Exploratory study of biomarkers for liver fibrosis assessment using non-invasive samples
- Conditions
- onalcoholic Fatty Liver Disease
- Registration Number
- JPRN-UMIN000050863
- Lead Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Not provided
Common items: - Ethanol hypersensitivity - Persons who have experienced skin irritation by adhesive tapes - Alcohol consumption >= 30 g/day (males) or >= 20 g/day (females). - Taking supplements such as vitamin and Minerals within 1 week of the day of sample collection (However, drugs including vitamins and minerals that are continuously used as therapeutic drugs for diseases are excluded.) - Prior surgery of the pancreatic and gallbladder system - Researchers involved in this research - the doctor judges it difficult for you to participate For healthy volunteers: - Hepatobiliary disease and medical history - Abdominal echo shows fatty liver For patients with nonalcoholic fatty liver disease: - Moderate or severe renal impairment (eGFR < 60 mL/min/1.73 m^2) - other hepatobiliary disorders are suspected; alcoholic liver disease, autoimmune liver disease, cholangitis, Alpha-1 antitrypsin deficiency, such as Wilson disease, Drug-induced liver injury, viral liver diseases such as HBV/HCV, cirrhosis, liver cancer, previous intravenous drug administration within 1 month before sample collection, Thyroid and adrenal disorders
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method